ProtekAI Overview

  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 2

ProtekAI General Information


Operator of a biotechnology research agency intended to be used for the development of protein-based drugs. The company's agency is working with a de novo fluorescent protein extracted from the marine organism Physalia, enabling clients to avail a new class of near-infrared fluorescent proteins, opening the door to a myriad of diagnostic & research applications

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Honolulu, HI
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ProtekAI Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Accelerator/Incubator 00000 Completed Startup
1. Early Stage VC 07-Dec-2010 00000 00000 00000 Completed Startup
To view ProtekAI’s complete valuation and funding history, request access »

ProtekAI Cap Table

Stock # of Shares
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed 0,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
To view ProtekAI’s complete cap table history, request access »

ProtekAI Executive Team (2)

Name Title Board Seat Contact Info
Barry Weinman Chairman
You’re viewing 1 of 2 executive team members. Get the full list »

ProtekAI Board Members (1)

Name Representing Role Since
Barry Weinman Self Chairman 000 0000
To view ProtekAI’s complete board members history, request access »

ProtekAI Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
University of Hawaii Foundation Limited Partner Minority 000 0000 000000 0
HiBEAM Accelerator/Incubator Minority 000 0000 000000 0
To view ProtekAI’s complete investors history, request access »